airflusal forspiro
sandoz d.d. - salmeterolis/flutikazono propionatas - dozuoti įkvepiamieji milteliai - 50 µg/500 µg/dozėje; 50 µg/250 µg/dozėje - salmeterol and fluticasone
everio airmaster
zentiva k.s. - salmeterolis/flutikazono propionatas - dozuoti įkvepiamieji milteliai - 50 µg/500 µg/dozėje - salmeterol and fluticasone
fusamix easyhaler
orion corporation - salmeterolis/flutikazono propionatas - įkvepiamieji milteliai - 50 µg/250 µg/dozėje - salmeterol and fluticasone
fusamix easyhaler
orion corporation - salmeterolis/flutikazono propionatas - įkvepiamieji milteliai - 50 µg/500 µg/dozėje - salmeterol and fluticasone
seretide diskus
glaxosmithkline trading services limited - salmeterolis/flutikazono propionatas - dozuoti įkvepiamieji milteliai - 50 µg/100 µg/dozėje; 50 µg/500 µg/dozėje; 50 µg/250 µg/dozėje - salmeterol and fluticasone
serkep
viatris limited - salmeterolis/flutikazono propionatas - suslėgtoji įkvepiamoji suspensija - 25 µg/125 µg/dozėje; 25 µg/250 µg/dozėje - salmeterol and fluticasone
flamerio
elpen pharmaceutical co. inc. - salmeterolis/flutikazono propionatas - dozuoti įkvepiamieji milteliai - 50 µg/250 µg/dozėje; 50 µg/500 µg/dozėje - salmeterol and fluticasone
seretide inhaler
glaxosmithkline trading services limited - salmeterolis/flutikazono propionatas - suslėgtoji įkvepiamoji suspensija - 25 µg/125 µg/dozėje; 25 µg/50 µg/dozėje; 25 µg/250 µg/dozėje - salmeterol and fluticasone
nordimet
nordic group b.v. - metotreksatas - arthritis, psoriatic; psoriasis; arthritis, juvenile rheumatoid; arthritis, rheumatoid - antinavikiniai vaistai - nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.
koselugo
astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antinavikiniai vaistai - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.